相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pharmacogenetics of siponimod: A systematic review by Diaz-Villamarin et al. - Information is power
Pablo Zubiaur et al.
BIOMEDICINE & PHARMACOTHERAPY (2023)
Multiple sclerosis and COVID-19: The Swedish experience
Anne-Marie Landtblom et al.
ACTA NEUROLOGICA SCANDINAVICA (2021)
Severe lymphopenia switching from Fingolimod to Siponimod
Maddalena Sparaco et al.
NEUROLOGICAL SCIENCES (2021)
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs
Katherine N. Theken et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2020)
Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden Outlier or predecessor?
S. G. Berntsson et al.
ACTA NEUROLOGICA SCANDINAVICA (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Real World Lab Data: Patterns of Lymphocyte Counts in Fingolimod Treated Patients
Maxi Kaufmann et al.
FRONTIERS IN IMMUNOLOGY (2018)
Approach to Fingolimod-Induced Lymphopenia in Multiple Sclerosis Patients: Do We Have a Roadmap?
Jagannadha Avasarala et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update
J. A. Johnson et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
A pragmatic approach to dealing with fingolimod-related lynnphopaenia in Europe
Gavin Giovannonin et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2015)
Multiple sclerosis rebound after fingolimod discontinuation for lymphopenia
Loredana La Mantia et al.
NEUROLOGICAL SCIENCES (2014)
Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia
Clemens Warnke et al.
NEUROLOGY (2014)
分享论文
